Dyslipidemia management requires a multifaceted approach that includes both lifestyle modifications and pharmacotherapy. The primary goal of treatment is to reduce LDL-C levels to lower cardiovascular (CV) risk. Additionally, some patients may require other therapies to address residual CV risk associated with elevated triglycerides or elevated lipoprotein(a) [Lp(a)].
The 2018 AHA/ACC/Multisociety cholesterol guideline emphasized the importance of lowering LDL-C as the primary treatment target. This guideline focuses on populations where statin therapy has been proven to lower both LDL-C and CV event risk, known as the four statin benefit groups. In 2022, the ACC published an Expert Consensus Decision Pathway for nonstatin therapy, recommending specific LDL-C thresholds for all four statin benefit groups, rather than just two as per the 2018 guideline. While statin therapy is effective in reducing CV risk and LDL-C levels, some patients may require additional nonstatin therapies to achieve optimal LDL-C reduction. Several nonstatin therapies, including ezetimibe, bempedoic acid, PCSK9 monoclonal antibodies, and inclisiran, are available and effective in further lowering LDL-C. This program will review these LDL-C lowering therapies and their optimal use to improve patient outcomes.
Even when LDL-C is reduced to recommended levels, patients with elevated triglycerides or Lp(a) remain at increased risk for CV events. Clinicians should be aware of the evidence linking elevated triglycerides and Lp(a) with CV events, as well as the latest innovations and outcomes data related to current and emerging drug therapies for these conditions. This session will review outcomes data on the use of omega-3 fatty acids in patients with elevated triglycerides. Additionally, it will cover two medications in phase III trials, pelacarsen and olpasiran, which lower Lp(a) in conjunction with statin therapy.
Planning Committee Disclosure - No relevant relationships
All members of the PESI, Inc. planning committee have provided disclosures of financial relationships with ineligible organizations and any relevant non-financial relationships prior to planning content for this activity. None of the committee members had relevant financial relationships with ineligible companies or other potentially biasing relationships to disclose to learners. For speaker disclosures, please see the faculty biography.
NOTE: Tuition includes one free CE Certificate (participant will be able to print the certificate of completion after passing the online post-test (80% passing score) and completing the evaluation). Instructional methods will include PowerPoint, didactic lecture, and others.
Continuing Education Information: Listed below are the continuing education credit(s) currently available for this non-interactive self-study package. Program content is reviewed periodically per accrediting board rules for currency and appropriateness for credit. Credit approvals are subject to change. Please note, your state licensing board dictates whether self-study is an acceptable form of continuing education, as well as which credit types are acceptable for continuing education hours. Please refer to your state rules and regulations. If your profession is not listed, please contact your licensing board to determine your continuing education requirements and check for reciprocal approval.
For other credit inquiries not specified below, please contact info@pesi.com or 800-844-8260 before purchase.
Materials that are included in this course may include interventions and modalities that are beyond the authorized practice of your profession. As a licensed professional, you are responsible for reviewing the scope of practice, including activities that are defined in law as beyond the boundaries of practice in accordance with and in compliance with your profession's standards.
For Planning Committee disclosures, please see the statement above. For speaker disclosures, please see the faculty biography.
Earn up to 2.0 CE hours. Please see below, for more details, as credit amounts vary by state and profession.
This self-study program offers 120 instructional minutes of pharmacology content which is designed to qualify for 2.0 contact hours toward your pharmacology requirement.
PESI, Inc. is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. Nurses completing these self-study materials will earn 2.0 contact hours. Expires: 11/11/2027.
PESI, Inc. is a provider approved by the California Board of Registered Nursing, Provider #: 17118 for 2.0 self-study contact hours.
** You will need to provide your license number to PESI. PESI must have this number on file in order for your hours to be valid.
PESI, Inc. is an approved provider by the Florida Board of Nursing. Provider #: FBN2858. These materials qualify for 2.0 self-study contact hours.
PESI, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This activity was originally recorded on 12/12/2024. It was last reviewed on 10/25/2024 and is valid until 10/25/2027. You are required to successfully complete and submit a post-test prior to receiving a certificate of completion.
PESI, Inc. designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME such as PESI. Physician assistants may receive a maximum of 2.0 hours for completing this self-study program. This activity was originally recorded on 12/12/2024. It was last reviewed on 10/25/2024 and is valid until 10/25/2027.
PESI, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. PESI, Inc. designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™.
This self-study activity qualifies for 2.0 continuing education clock hours as required by many national, state and local licensing boards and professional organizations. Save your activity advertisement and certificate of completion, and contact your own board or organization for specific requirements.
| File type | File name | Number of pages | |
|---|---|---|---|
| Manual - Lipid Logic: An Update on Current and Future Pharmacologic Approaches to Dyslipidemia Management (3 MB) | 42 Pages | Available after Purchase |
Joseph Saseen, PharmD, BCPS, BCACP, CLS, FASHP, FCCP, FAPhA, MNLA is Associate Dean for Clinical Affairs and Professor of Clinical Pharmacy and a Professor of Family Medicine at the University Anschutz Medical Campus. He has responsibilities for enhancing the school’s clinical enterprise, further developing sustainable clinical service models, advocating for advancing the practice of pharmacy in the state of Colorado, and manages strategic international relationships.
Dr. Saseen is a clinical pharmacist who focuses on cardiovascular risk reduction and population health. His scholarly work includes over two hundred peer-reviewed publications and book chapters. He is a past president of the National Lipid Association (NLA). Dr. Saseen is a fellow of the American College of Clinical Pharmacy, American Society of Health-system Pharmacists, American Pharmacists Association, and the American Heart Association. He is a Master of the NLA and is certified as a Clinical Lipid Specialist. He was an author of the 2018 AHA/ACC/Multisociety cholesterol management guideline, the 2022 NLA Statin Intolerance Scientific Statement, and the 2024 NLA/American Geriatrics Society Managing Hypercholesterolemia in Adults Aged 75 Years and Older Without a History of ASCVD Expert Consensus Statement.
Speaker Disclosures:
Access never expires for this product.
Visit our FAQ page at www.pesi.com/faq or contact us at www.pesi.com/info
Satisfaction Guarantee
Your satisfaction is our goal and our guarantee. Concerns should be addressed to: PO Box 1000, Eau Claire, WI 54702-1000 or call 1-800-844-8260.
ADA Needs
We would be happy to accommodate your ADA needs; please call our Customer Service Department for more information at 1-800-844-8260.
PESI Mobile App
Access CE trainings on your phone or tablet through our free mobile app. Choose video or audio-only versions of online courses from the world’s best instructors, and complete your CE requirements anywhere, anytime, at your own pace.
Please wait ...
